3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Cystadenocarcinoma, Serous
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Ameloblastoma
1
Interventions
Paclitaxel
6
liposomal doxorubicin
4
Carboplatin
4
Topotecan
3
Drug Therapy
3
Gemcitabine
2
Doxorubicin
2
Bevacizumab
2
1-dodecylpyridoxal
2
trametinib
1
saracatinib
1
pertuzumab
1
pembrolizumab
1
pegfilgrastim
1
olaparib
1
masitinib
1
dabrafenib
1
cyclopropapyrroloindole
1
cobimetinib
1
cediranib
1
atezolizumab
1
aflibercept
1
abagovomab
1
Vemurafenib
1
Trastuzumab
1
Taxes
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Neoadjuvant Therapy
1
NP-G2-044
1
Magnetic Resonance Spectroscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Ovarian Neoplasms
×
trametinib
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled